News|Articles|November 20, 2026

Sanofi Eyes Insmed in Potential $43B Deal as Dupixent Patent Clock Ticks

Listen
0:00 / 0:00

Key Takeaways

  • A potential $35–$43 billion Insmed purchase would represent one of the largest biopharma transactions since Pfizer–Seagen, and would be challenging to execute as an all-cash deal.
  • Dupixent generated €5.7 billion in Q3 revenue (~40% of group sales), making the early-2030s patent cliff the central strategic driver for external growth.
SHOW MORE

Sanofi is exploring a $35B–$43B takeover of Insmed and its blockbuster lung drug Brinsupri as the French pharma giant braces for Dupixent’s looming patent expiration.

Sanofi is evaluating a potential acquisition of U.S. drugmaker Insmed, according to a Bloomberg report published November 19, with the French pharma giant working with advisers to assess a deal that could be valued between $35 billion and $43 billion. If completed at the high end of that range, it would rank as the largest biopharma buyout since Pfizer’s $43 billion acquisition of Seagen in 2023.

Neither company has commented on the report, which cited anonymous sources. Insmed shares surged roughly 18% to $141.87 on the news, while Sanofi shares slipped about 2% to $46.15.

The strategic logic centers on Dupixent, Sanofi’s blockbuster biologic for inflammatory conditions including eczema and asthma, which generated €5.7 billion in third-quarter revenue — nearly 40% of Sanofi’s total group sales. The drug is on track toward patent expiration in the early 2030s, leaving a significant revenue hole that CEO Belén Garijo has repeatedly flagged as the company’s defining challenge. Garijo has told investors the organization is squarely focused on managing the post-Dupixent transition over the next decade, with M&A and licensing alongside improved R&D productivity as the primary levers.

Insmed offers a compelling answer to that problem. Its lead product, Brinsupri (brensocatib), a DPP1 inhibitor approved for non-cystic fibrosis bronchiectasis, generated $400 million in third-quarter sales alone. The company projects full-year 2026 revenue of $1.8 billion to $1.9 billion across its portfolio, which also includes Arikayce — a treatment for refractory Mycobacterium avium complex lung disease that posted $124 million in Q3 sales with full-year guidance of $460 million to $470 million.

The broader pipeline

Beyond its marketed products, Insmed carries a pipeline with significant upside. Its lead investigational asset, treprostinil palmitil inhalation powder (TPIP), is in the Phase 3 PALM program across four indications: pulmonary hypertension associated with interstitial lung disease, pulmonary arterial hypertension, progressive pulmonary fibrosis, and idiopathic pulmonary fibrosis. Insmed projects peak annual sales above $6 billion for TPIP. The pipeline also includes early-stage candidates targeting rheumatoid arthritis, inflammatory bowel disease, and Duchenne muscular dystrophy.

The price tag, however, is a formidable obstacle. At $35 billion to $43 billion, Sanofi could not fund an all-cash transaction without taking on substantial debt, and analysts have pointed to Insmed’s elevated valuation as the chief barrier to a deal getting done. Bloomberg Intelligence analysts John Murphy and Aude Gerspacher noted that Garijo faces a core challenge familiar to Sanofi: improving a historically underperforming R&D organization while securing new growth sources to fill the Dupixent void.

The report adds to a string of strategic moves by Sanofi in recent months. The company completed a $9.5 billion acquisition of Blueprint Medicines in 2025 to build out its rare disease portfolio, and has been vocal about reviewing its pipeline for underperforming assets. On its second-quarter earnings call this year, Sanofi attributed recent pipeline setbacks to weak decision-making rather than weak science — a candid admission that underscored the urgency of its strategic reset under Garijo.

Insmed’s CFO Sara Bonstein departed the company on October 30 after nearly seven years in the role, an executive transition that adds a layer of uncertainty ahead of any potential transaction.

In September 2025, Pharmaceutica Executive spoke with Sanofi’s then-CEO Paul Hudson on the company’s decision-making process. He explained, “We chase the miracles of science to improve people’s lives. People are looking for miracles. I get letters every day saying, ‘tell me you’re working on this disease because the doctors say there is nothing for me.’ That’s why it has to be miracles.”

Source

  1. Sanofi Weighs Takeover of US Drugmaker Insmed Bloomberg November 19, 2026 https://www.bloomberg.com/news/articles/2026-11-19/sanofi-weighs-takeover-of-us-drugmaker-insmed

Related to this article